A new biomarker has been identified, which indicates the progression of the disease in the patient and their response to specific drug therapies, reveals a new study. Scientists at the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions including Colorado State University and Fred Hutchinson Cancer Center reported results from a glioblastoma study in the issue of Cancer Research.
‘Further research is required to develop a diagnostic test that can help physicians understand and treat patients better.’
Tweet it Now
Glioblastoma is a highly aggressive and heterogeneous form of brain cancer, with a median survival time from diagnosis of just one year. Previous efforts to classify glioblastoma tumors into molecular subtypes for precision treatment have been largely unsuccessful.In this study, scientists developed an innovative computational method to classify tumors based on their dependency on a molecule, known as BUB1B, that some glioblastomas need to survive.
The project revealed new tumor subtypes and found that BUB1B-sensitive tumors had significantly worse prognosis but were more likely to respond to many drugs already in clinical use.
"It was truly remarkable to see our predictive model yield a new set of molecular subtypes, which appear to be far more indicative of prognosis and therapeutic response than existing subtypes," said Jun Zhu, PhD, Head of Data Sciences at Sema4, Professor of Genetics and Genomic Sciences at Mount Sinai, and senior author of the paper.
"For patients who receive the grim diagnosis of glioblastoma, this signals new hope for tailored treatment more likely to be effective against their cancer."
Advertisement
Eric Schadt, PhD, Sema4 CEO and Dean for Precision Medicine at Mount Sinai, added:
Advertisement
Source-Eurekalert